NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Vaccine Response With NT-I7
Phase 1
Withdrawn
- Conditions
- Bladder CarcinomaBreast CarcinomaColorectal Adenocarcinoma
- Interventions
- Biological: Recombinant human IL-7-hyFc (NT-I7)Biological: Vaccine sequence 1Biological: Vaccine sequence 2
- First Posted Date
- 2019-08-13
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT04054752
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer
Phase 1
Active, not recruiting
- Conditions
- Localized Breast CarcinomaRecurrent Breast CarcinomaTriple-Negative Breast CarcinomaBilateral Breast CarcinomaHER2-Negative Breast Carcinoma
- Interventions
- Procedure: Biospecimen CollectionOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationRadiation: Radiation Therapy
- First Posted Date
- 2019-08-12
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT04052555
- Locations
- 🇺🇸
University of Texas Medical Branch, Galveston, Texas, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Farmington Health Center, Farmington, Utah, United States
A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer
Phase 2
Withdrawn
- Conditions
- Papillomavirus InfectionsOropharyngeal Neoplasms
- Interventions
- Biological: E7 TCR
- First Posted Date
- 2019-08-05
- Last Posted Date
- 2020-09-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT04044950
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Pediatric cGVHD Symptom Scale
Recruiting
- Conditions
- Graft vs Host Disease
- First Posted Date
- 2019-08-05
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 420
- Registration Number
- NCT04044365
- Locations
- 🇺🇸
Children's Healthcare of Atlanta - Egleston Hospital, Atlanta, Georgia, United States
🇺🇸Children's Hospital Colorado (CHCO), Aurora, Colorado, United States
🇺🇸Fred Hutchinson Cancer Center (FHCC), Seattle, Washington, United States
Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer
Phase 2
Active, not recruiting
- Conditions
- Fallopian Tube Endometrioid TumorFallopian Tube High Grade Serous AdenocarcinomaRecurrent Fallopian Tube Endometrioid AdenocarcinomaRecurrent Ovarian Serous AdenocarcinomaRecurrent Primary Peritoneal Endometrioid AdenocarcinomaMalignant Ovarian Endometrioid TumorPlatinum-Sensitive Ovarian CarcinomaRecurrent Ovarian Endometrioid AdenocarcinomaOvarian High Grade Serous AdenocarcinomaPlatinum-Sensitive Fallopian Tube Carcinoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2019-07-29
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 61
- Registration Number
- NCT04034927
- Locations
- 🇺🇸
Women and Infants Hospital, Providence, Rhode Island, United States
🇺🇸UCHealth University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸University of Virginia Cancer Center, Charlottesville, Virginia, United States
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors
Phase 1
Completed
- Conditions
- Neoplasms With Mesothelin ExpressionEpithelioid MesotheliomaCholangiocarcinoma, ExtrahepaticAdenocarcinoma, Pancreatic
- Interventions
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 19
- Registration Number
- NCT04034238
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis
Phase 2
Completed
- Conditions
- Esophagogastric JunctionGastric AdenocarcinomaGastric CancerPeritoneal Carcinomatosis
- Interventions
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT04034251
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Phase 2
Terminated
- Conditions
- Adenocarcinoma of LungNon-Small Cell Lung CancerLung Cancer
- Interventions
- Diagnostic Test: Mesothelin ExpressionDiagnostic Test: TrueSight Oncology 500
- First Posted Date
- 2019-07-22
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 6
- Registration Number
- NCT04027946
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral
Phase 2
Withdrawn
- Conditions
- Metastatic Hepatocellular CarcinomaHepatocellular Carcinoma
- Interventions
- First Posted Date
- 2019-07-19
- Last Posted Date
- 2020-03-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT04025567
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer
Phase 2
Terminated
- Conditions
- Oropharyngeal NeoplasmsPapillomavirus Infections
- Interventions
- Biological: E7 T-Cell Receptor (TCR)
- First Posted Date
- 2019-07-11
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1
- Registration Number
- NCT04015336
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath